Table 1 SETBP1 mutations in chronic myelomonocytic leukemia
From: SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome
Reference | Number of Patients | Mutation Prevalence | Impact on Survival |
|---|---|---|---|
[38] | 195 | 12 (6.2%) | Yes (p-0.028) |
[39] | 179 | 8 (4.5%) | Yes (p = 0.01) |
[32] | 294 | 21 (7.1%) | No (p-0.798) |
[31] | 152 | 22 (14.5%) | Yes (p-NR for CMML cohort) |
[33] | 466 | 21 (5%) | No (p-0.07) |
[40] | 145 | 26 (18%) | No (p-NR) |
[45] | 214 – Learning 260 – Validation | 19 (8.9%) – Learning 24 (9.2%) – Validation | Yes (p-0.04) |
[43]* | 1364 | NR | Yes (p < 0.001) |